In the News
ICON experts frequently author or contribute to industry trade press.
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category.
-
Improving early phase oncology clinical trial design: An opportunity for statisticians
In this article, our experts offer their insights on the use of rule-based study designs in early phase oncology development programs.
-
Life sciences sector remains strong in Ireland despite challenges
Brendan Brennan outlines the importance of collaboration between industry and academia in this article from the Irish Times Life Sciences special report.
2022 The Irish Times DAC
-
.jpg?w=545&itok=2UoAgS5y "ipt_thumbnail_170x170-(1)")
Turning an ocean of data into actionable wisdom to support optimal site identification
Travis Caudill, VP Feasibility & Clinical Informatics, offers his insights on how advancements in AI can help the pharmaceutical industry identify the best sites for their clinical trials through the harnessing of Big Data.
Innovations in Pharmaceutical Technology, December 2022, pages 24-25. Samedan Ltd
-
Ensuring success in pharmacovigilance and patient safety
This article explores opportunities for outsourcing pharmacovigilance services, potential models, and best practices for selecting a service provider.
-
Life sciences industry an active player in pandemic response
Rose Kidd outlines the role ICON played in the global response to the COVID-19 pandemic in the Irish Times Life Sciences special report.
2022 The Irish Times DAC
-
Boon and bane: dodging participant burden in decentralised clinical trials
As DCT adoption increases, Harpreet Gill, Head of Decentralised Clinical Trial Solutions at ICON contributes to this piece in Clinical Trials Arena which looks at how sponsors and CROs must mind the risk of adding patient burden while designing decentralised trials.
Verdict Media Limited 2022
-
The evolving relationship between sponsors and contract research organisations
If the last few years have taught us anything, it’s that so much more can be achieved when all players in the life sciences and pharmaceutical industries work together in a truly collaborative way. The opportunity for the clinical development industry is to take what we have learned about how we can work together and use this to continue to drive progress. To strategically support clients, at ICON, this means partnering with sponsors in a way that goes beyond a traditional CRO. It means being a trusted partner.
In this podcast and article Jeff James, EVP Alliance Management, offers his perspective on what it takes to be a trusted partner to sponsors in the clinical development industry. -
Measuring the cost-effectiveness of vaccines targeting infectious diseases
ICON's Richard Pitman and Pragya Khurana provide insights on the use of real world evidence to build cost-effectiveness models that demonstrate the value that vaccines bring to healthcare systems.
-
Drug development practices to improve public health policy
In this article, Dr Andrew Garrett, Executive Vice President of Scientific Operations, explores the need for interdisciplinary collaboration between pharmaceutical and non-pharmaceutical researchers and public health centres to consider the overlap between NPIs and PIs and identify where standards can be improved and enforced.
-
Responsive strategies in vaccine development
Shelley McLendon discusses the importance of disease surveillance, developments in early outbreak detection, and the role of smart data reporting and adaptive trial designs.
.jpg?w=340&itok=mGqXs8KJ "ipt_thumbnail_170x170-(1)"){kind=icon}
